Clinical trials: Tumor Pancreas
Pancreatic Cancer
Impact of Three-dimensional Visualization on Operation Strategy and Complications for Pancreatic Cancer
The aim of the multi-centre study is to evaluate correctly the impact of three dimensional visualization on operation strategy and complications for Pancreatic Cancer.
- Trial name
- NCT03749005
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhujiang Hospital
High Risk Localised Pancreatic Cancer
Span-C-SBRT for Pancreatic Cancer
To assess the freedom from local failure at 12 months after Stereotactic Body Radiotherapy (SBRT). Also to assess the safety, efficacy and feasibility of SBRT in the treatment of high risk localised pancreatic cancer.
- Trial name
- Span-C (NCT03505229)
- Testing
- Stereotactic Body Radiotherapy (SBRT)
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- Royal North Shore Hospital
Pancreatic Cancer
A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection
This is a two-arm, open-label, phase II study of in adult patients who have successfully undergone R0/R1 resection of PDAs following neoadjuvant chemotherapy and completion of adjuvant chemotherapy.
- Trial name
- NCT03038477
- Testing
- Durvalumab
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Pancreatic Cancer
CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer
The purpose of this study is to treat participants with the combination of CPI-613 (the study drug) with FOLFIRINOX (the standard combination of drugs) to determine if it is safe and effective for participants with localized and…
- Trial name
- NCT03699319
- Testing
- CPI 613, Oxaliplatin, Irinotecan
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- David Bajor, MD
Pancreatic Neoplasms
Analgesia and Pancreatic Cancer Surgery
Long-term survival for patients with pancreatic carcinoma is low, even following resection, the 5-year survival rate of patients ranges from 10 to 25%1.
- Trial name
- NCT01929915
- Testing
- Epidural patient controlled analgesia, Intravenous patient controlled analgesia
- Where
- Taiwan
- Volunteers
- 135 people
- Sponsor
- National Taiwan University Hospital
Pancreatic Carcinoma, Pancreatic Neuroendocrine Tumor
Study on Microflora Characteristics of Pancreatic Solid Lesions Via Endoscopic Ultrasound-guided Fine Needle Aspiration/Biopsy
Study objective: To describe the microflora characteristics of the pancreatic solid lesions via the tissue acquired via the endoscopic ultrasound-guided fine needle aspiration/biopsy (EUS-FNA/B).
- Conditions
- Pancreatic Carcinoma, Pancreatic Neuroendocrine Tumor, Autoimmune Pancreatitis, Microflora
- Trial name
- NCT05171517
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking Union Medical College Hospital
Hepatocellular Cancer, Cholangiocarcinoma
The PLATON Network
The PLATON Network study is designed to elevate personalized therapy based on genomic tumor profiles in gastrointestinal cancer patients. Hereby, PLATON's study-design focuses on the patient's tumor molecular profiling.
- Conditions
- Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer
- Trial name
- PLATON (NCT05489250)
- Where
- 31 sites in Germany
- Volunteers
- 565 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma
Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas Cancer
To evaluate the normalization rate of CA 19-9 of individuals with non-metastatic pancreas cancer following up to 6 months of neoadjuvant chemotherapy.
- Conditions
- Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
- Trial name
- NCT04669197
- Testing
- Paclitaxel protein bound, Gemcitabine, Cisplatin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- HonorHealth Research Institute
Pancreatic Cancer, Adenocarcinoma of the Pancreas
Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer
The purpose of this study is to evaluate the safety and tolerability of the combined treatment of Sorafenib (BAY 43-9006) with Gemcitabine and radiotherapy in patients with localized unresectable pancreatic cancer.
- Trial name
- NCT00375310
- Testing
- Gemcitabine, Sorafenib, Radiotherapy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Indiana University
Pancreatic Pseudocyst
Endoscopic Ultrasound-guided Drainage of Pancreatic Pseudocysts
The purpose of this study is to compare the effect of lumen-apposing metal stent (LAMS) and traditional plastic stent on the drainage of pancreatic pseudocyst, mainly to observe the cyst recurrence rate of 12 months after…
- Trial name
- NCT03022110
- Testing
- Endoscopic Ultrasound-guided Drainage
- Volunteers
- 106 people
- Sponsor
- Yiqi Du
Colorectal Cancer, Pancreatic Cancer
Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers
Colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) are the most common gastrointestinal cancers in Western countries and are both associated with significant morbidity and mortality.
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Metastatic Cancer, Advanced Cancer
- Trial name
- MEDIPLEX (NCT02777710)
- Testing
- Pexidartinib, Durvalumab
- Where
- 2 sites in France
- Volunteers
- 48 people
- Sponsor
- Centre Leon Berard
Breast Cancer, Ovarian Cancer
A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
Chimeric antigen receptor T cells (CAR-T) therapy has not yet been fully explored in solid tumors. Human epidermal growth factor receptor-2(HER2) is widely expressed in cancers.
- Conditions
- Breast Cancer, Ovarian Cancer, Lung Cancer, Gastric Cancer
- Trial name
- NCT02713984
- Testing
- Anti-HER2 CAR-T
- Where
- China
- Sponsor
- Zhi Yang
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
- Trial name
- MOONRAY-01 (NCT06586515)
- Testing
- LY3962673, Cetuximab, Gemcitabine
- Where
- 52 sites in United States, Canada and 7 more
- Volunteers
- 630 people
- Sponsor
- Eli Lilly and Company
Pancreatic Cancer
Nab-paclitaxel Plus S-1(AS) Versus Nab-paclitaxel Plus Gemcitabine(AG) in Patients With Advanced Pancreatic Cancer
This is a randomized phase II trial comparing the first-line treatment with nab-paclitaxel plus S-1(AS) and nab-paclitaxel plus gemcitabine(AG) in advanced pancreatic ductal adenocarcinoma (PDA) with primary tumor nonexcision in…
- Trial name
- ASAGPAC (NCT03636308)
- Testing
- nanoparticle albumin-bound paclitaxel, S1, Gemcitabine
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University
Chronic Pancreatitis, Pancreatic Cancer
Blood Biomarkers and Gut Microbiota for Pancreatic Cancer Risk in Chronic Pancreatitis
The goal of this observational study is to learn more about pancreatic cancer risk in people with chronic pancreatitis. Researchers will study blood markers and gut microorganisms, which are bacteria and other microbes living in…
- Trial name
- NCT07762950
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
Extrahepatic Bile Duct Cancer, Gastric Cancer
Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells.
- Conditions
- Extrahepatic Bile Duct Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Liver Cancer
- Trial name
- NCT00019474
- Testing
- filgrastim, recombinant interferon alfa, fluorouracil
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Montefiore Medical Center
Advanced Solid Tumor, Ovarian Cancer
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
NUV-868-01 is a first-in human, open- label, Phase 1/2 dose escalation and expansion study in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Ovarian Cancer, Ovary Cancer, Cancer of Ovary
- Trial name
- NCT05252390
- Testing
- NUV-868, Olaparib, Enzalutamide
- Where
- 22 sites in United States, Australia
- Volunteers
- 82 people
- Sponsor
- Nuvation Bio Inc.
Pancreatic Ductal Adenocarcinoma
Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer
A Prospective Study on the Efficacy and Safety of CD8+NKG2D+ AKT cell immunotherapy to the pancreatic cancer patients treated with adjuvant chemotherapy.
- Trial name
- AKT (NCT02929797)
- Testing
- CD8+NKG2D+ AKT Cell, Gemcitabine
- Where
- 2 sites in China
- Volunteers
- 72 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Unresectable Pancreatic Cancer
Bioinformation Therapy for Pancreatic Cancer
The aim of this study is the synergistic effect of cancer ablation and life information rehabilitation therapy on unresectable pancreatic cancer.
- Trial name
- NCT03239184
- Testing
- Cancer ablation, Life information rehabilitation therapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.